SYNAIRGEN LIMITED

1. Credit Opinion: CONDITIONAL A definitive approval cannot be issued due to the absence of quantitative financial data in the provided records, which prevents a standard ratio analysis. The credit opinion is conditional pending the submission of audited financials and intercompany agreements. The company has recently undergone a major structural transition, converting from a Public Limited Company (PLC) to a Private Limited Company, and is now majority-controlled by TFG Asset Management UK LLP. While this take-private transaction likely implies stronger parental backing, the restructuring introduces transitional risk, and the biotechnology sector inherently carries high cash burn and pre-revenue risks that require close examination.

2. Financial Strength A standalone financial strength assessment is currently impossible due to missing balance sheet data (no figures for fixed/current assets, liabilities, or net assets). The stated share capital is only £11, which is negligible and highly typical of a subsidiary vehicle following a corporate reorganisation. The recent transition from a PLC to a private entity under the >75% control of TFG Asset Management suggests that Synairgen's financial strength is now inextricably linked to its parent. Creditworthiness will depend heavily on the strength of TFG Asset Management's balance sheet and their willingness to inject capital, rather than Synairgen's standalone solvency.

3. Cash Flow Assessment Without cash flow statements or working capital figures, a direct liquidity assessment cannot be completed. However, operating as a biotechnology R&D firm (SIC 72110) strongly indicates that the company is pre-revenue or operating at a loss, with significant negative operating cash flows required to fund clinical trials and research. Liquidity and working capital are almost certainly sustained through intercompany funding or equity injections from the majority shareholder (TFG Asset Management) rather than organic trade cash flows. It is critical to verify that these funding lines are structural (equity) rather than callable debt, which could precipitate a liquidity crisis.

4. Monitoring Points - Parent Company Support: Secure explicit comfort letters or parent company guarantees from TFG Asset Management UK LLP to ensure liquidity is maintained. - Intercompany Debt: Review the structure of any intercompany balances. Debt owed to the parent could be subordinated, but if it is callable on demand, it poses a severe liquidity risk. - Cash Burn Rate: Once financials are available, closely monitor the monthly cash burn rate and the remaining cash runway to ensure the company can meet its R&D milestones before requiring further capital raises. - Management Stability: Track board composition following the recent director resignations (March 2026). High turnover at the board level following a take-private transaction can indicate strategic pivots or integration challenges.